This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combined Application of EBUS and EUS in Lung Cancer

This study has been completed.
Information provided by:
National Cancer Center, Korea Identifier:
First received: June 23, 2011
Last updated: October 17, 2012
Last verified: June 2011
This study aims to investigate a diagnostic yield and performance characteristics according to the order of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) and endoscopic ultrasound-with bronchoscope-guided transbronchial needle aspiration (EUS-B-FNA) in the mediastinal staging of potentially operable lung cancer. EUS-FNA is a better tolerated procedure than EBUS-TBNA. Therefore, EUS-B-FNA can be the main procedure in a combined approach with EBUS-TBNA and EUS-B-FNA. In group A, the investigators perform EBUS-TBNA first and EUS-B-FNA is performed when necessary. In group B, EUS-B-FNA is first applied and EBUS-TBNA is performed when necessary. The hypothesis is that the diagnostic yield of the EUS centered procedure is as good as that of the EBUS centered procedure and the EUS centered procedure is more tolerable than the EBUS centered procedure. We evaluate diagnostic yields and performance characteristics of each group.

Condition Intervention
Non Small Cell Lung Cancer Procedure: EUS-B-FNA followed by EBUS-TBNA Procedure: EBUS-TBNA followed by EUS-B-FNA

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: Combined Application of EBUS-TBNA and EUS-B-FNA in Mediastinal Staging of Lung Cancer; EBUS-TBNA Centered Procedure vs. EUS-B-FNA Centered Procedure, a Randomized Study.

Resource links provided by NLM:

Further study details as provided by National Cancer Center, Korea:

Primary Outcome Measures:
  • Diagnostic accuracy [ Time Frame: When the confimative disgnosis is available in all subjects (after surgery) ; 8-12 months ]

Secondary Outcome Measures:
  • Procedure time [ Time Frame: During and just after the procedure ; 5-60 minutes ]
  • Cardiovascular measurement (change of blood pressure, changes of heart rate, number of patients with arrhythmia) [ Time Frame: During the procedure; 0-60 minutes ]
  • Degree of desaturation [ Time Frame: During the procedure; 0-60minutes ]
  • Discomfort by the procedure [ Time Frame: After the procedure ; 2-3hr ]
  • Number of participants with adverse Events (infection, bleeding requiring intervention, pneumothorax, or any complications requiring hospital admission) [ Time Frame: During and after the procedure; 0-2 weeks ]
  • Lymph node features [ Time Frame: During and after the procedure; 0-2hrs ]
  • Fentanyl/midazolam/lidocaine consumption [ Time Frame: After the procedure ; 1-2 hrs ]

Enrollment: 162
Study Start Date: June 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A
EBUS centered
Procedure: EUS-B-FNA followed by EBUS-TBNA
EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
Experimental: Arm B
EUS centered
Procedure: EBUS-TBNA followed by EUS-B-FNA
EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed or strongly suspected non-small cell lung cancer (NSCLC)
  • Potentially operable patients

Exclusion Criteria:

  • M1 disease
  • Inoperable T4 disease
  • Mediastinal infiltration or extranodal invasion of the mediastinal lymph node visible on chest CT.
  • Confirmed supraclavicular lymph node metastasis
  • Pancoast tumors
  • Medically inoperable patients
  • Contraindications for bronchoscopy and esophageal endoscopy
  • Drug reaction to lidocaine, midazolam,fentanyl
  • Pregnancy
  • Ground glass-dominant nodule ( < 3cm)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01385111

Korea, Republic of
National Cancer Center (NCC) Korea
Goyang, Gyeonggi-do, Korea, Republic of, 410-769
Sponsors and Collaborators
National Cancer Center, Korea
Principal Investigator: Bin Hwangbo, MD, PhD Medical Doctor, Senior Researcher
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bin, Hwangbo, National Cancer center Identifier: NCT01385111     History of Changes
Other Study ID Numbers: NCC-EUSEBUS
Study First Received: June 23, 2011
Last Updated: October 17, 2012

Keywords provided by National Cancer Center, Korea:
endobronchial ultrasound
endoscopic ultrasound
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on September 19, 2017